GSK1324726A
目录号: PL13463 纯度: ≥98%
CAS No. :1300031-52-0
商品编号 规格 价格 会员价 是否有货 数量
PL13463-5mg 5mg ¥1421.82 请登录
PL13463-10mg 10mg ¥2472.73 请登录
PL13463-50mg 50mg ¥7047.27 请登录
PL13463-100mg 100mg ¥11498.18 请登录
PL13463-200mg 200mg 询价 询价
PL13463-500mg 500mg 询价 询价
PL13463-10mM*1mLinDMSO 10mM*1mLinDMSO ¥1570.18 请登录
Medlife所售产品仅用于科学研究(非临床研究),非药品不可食用,不可用于人体或动物的临床诊断和治疗,我们不为个人提供产品及服务。产品COA等资料,可至下方“质量控制”中下载。
中文名称
GSK1324726A
中文别名
4-[(2S,4R)-1-乙酰基-4-[(4-氯苯基)氨基]-2-甲基-1,2,3,4-四氢-6-喹啉基]苯甲酸;GSK1324726A (I-BET726) 抑制剂
英文名称
GSK1324726A
英文别名
Gsk1324726a;GSK-1324726A;I-BET726;4-[(2s,4r)-1-Acetyl-4-[(4-Chlorophenyl)amino]-2-Methyl-1,2,3,4-Tetrahydroquinolin-6-Yl]benzoic Acid;Benzoic acid, 4-[(2S,4R)-1-acetyl-4-[(4-chlorophenyl)amino]-1,2,3,4-tetrahydro-2-methyl-6-quinolinyl]-;C25H23ClN2O3;4-[(2S,4R)-1-Acetyl-4-[(4-chlorophenyl)amino]-2-methyl-1,2,3,4-tetrahydro-6-quinolinyl]benzoic acid;4bjx;4uyf;4uyg;4-((2S,4R)-1-Acetyl-4-((4-chlorophenyl)amino)-2-methyl-1,2,3,4-tetrahydroquinolin-6-;GSK1324726A
Cas No.
1300031-52-0
分子式
C25H23ClN2O3
分子量
434.91
包装储存
Powder -20°C 3 years;4°C 2 years
产品详情
GSK1324726A 是一种有效的选择性 BET 蛋白抑制剂,高亲和力结合到 BRD2 (IC50=41 nM),BRD3 (IC50=31 nM) 和 BRD4 (IC50=22 nM)。
生物活性
GSK1324726A is a novel, potent, and selective inhibitor of BET proteins with high affinity to BRD2 (IC 50 =41 nM), BRD3 (IC 50 =31 nM), and BRD4 (IC 50 =22 nM).
性状
Solid
IC50 & Target[1][2]
IC50: 22 nM (BRD4), 31 nM (BRD3), 41 nM (BRD2)
体外研究(In Vitro)
A panel of neuroblastoma cell lines are treated with GSK1324726A (I-BET726), and observed potent growth inhibition and cytotoxicity in most cell lines irrespective of MYCN copy number or expression level. All neuroblastoma cell lines tested exhibit potent growth inhibition, with a median growth IC50 value (gIC50; inhibitor concentration resulting in 50% growth inhibition) equal to 75 nM. has not independently confirmed the accuracy of these methods. They are for reference only.
体内研究(In Vivo)
GSK1324726A (I-BET726) inhibits neuroblastoma tumor growth. In the SK-N-AS model, mice in the vehicle group are euthanized on day 14 due to large tumor size. While there is no significant difference in tumor growth between the vehicle and GSK1324726A (5 mg/kg) group, 58% tumor growth inhibition (TGI) is observed in the GSK1324726A (15 mg/kg) group on day 14 of the study (n=9; p=0.006). Mice in the GSK1324726A (15 mg/kg) group are treated for an additional 7 days before tumor volume reaches a level comparable to that observed in the vehicle group, at which point the study is terminated. Tumors in the CHP-212 model grow much more slowly. After 42 days, tumors in vehicle-treated mice are only half the size those in the SK-N-AS model at the end of the study (Day 14). In the CHP-212 model, treatment with 5 mg/kg GSK1324726A results in TGI equal to 50% (n=8; p=0.1816), and mice in t
运输条件
Room temperature in continental US; may vary elsewhere.
储存方式
Powder -20°C 3 years;4°C 2 years
参考文献
[1]. Wyce A, et al. BET inhibition silences expression of MYCN and BCL2 and induces cytotoxicity in neuroblastoma tumor models. PLoS One. 2013 Aug 23;8(8):e72967.
[2]. Gosmini R, et al. The discovery of I-BET726 (GSK1324726A), a potent tetrahydroquinoline ApoA1 up-regulator and selective BET bromodomain inhibitor. J Med Chem. 2014 Oct 9;57(19):8111-31.
溶解度数据
In Vitro: DMSO : ≥ 46 mg/mL (105.77 mM)配制储备液
搜索质检报告(COA)

1:一般建议:溶解度为Medlife测试数据,可能与文献描述存在差异。这是由于生产工艺和批次不同产生的正常现象。为了使其更好的溶解,请用37℃加热试管并在超声波水浴中震动片刻。不同批次产品溶解度各有差异,仅做参考,具体以实验方案为准。

2:储存条件:粉末-20°C一般情况可以保存3年,溶于溶剂-80°C一般情况可以保存1年。不同产品及不同批次产品可能存在差异,请细致阅读产品信息,并辅助参考相关文献描述。

The molarity calculator equation
Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)
The dilution calculator equation
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
This equation is commonly abbreviated as: C1V1 = C2V2